Rapamycin and Sermorelin Interaction: Monitor | Peptide Database

Join others researching RAD-140 — share findings, ask questions, and learn from real experiences RAD-140 (Testolone) is a nonsteroidal investigational selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. for the potential treatment of muscle wasting conditions and hormone receptor-positive breast cancer. It was designed to provide the anabolic benefits of testosterone, specifically increased lean muscle mass and bone density, while minimizing androgenic side effects in tissues such as the prostate and skin. RAD-140 has demonstrated a high degree of tissue selectivity in preclinical models, with an anabolic-to-androgenic ratio substantially greater than that of testosterone. It entered Phase 1 clinical trials for metastatic breast cancer (ER+/HER2-) and has shown preliminary safety and tolerability in that context. However, RAD-140 is not approved for any medical use by any regulatory agency. It remains a research compound, and its widespread use in performance and physique enhancement contexts is based almost entirely on preclinical data and anecdotal reports rather than completed clinical trials for those indications. RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands. In preclinical studies, RAD-140 demonstrated potent anabolic effects on levator ani muscle mass comparable to testosterone, while showing significantly less stimulation of prostate weight. RAD-140 also crosses the blood-brain barrier and has demonstrated neuroprotective properties in in vitro models, reducing cell death caused by apoptotic insults in hippocampal neurons. At the molecular level, it activates AR-dependent gene transcription pathways involved in protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Importantly, RAD-140 does not undergo aromatization to estrogen and is not a substrate for 5-alpha reductase, meaning it does not produce estrogenic or DHT-mediated side effects. However, like all exogenous AR agonists, it suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis.

Join others researching Livagen — share findings, ask questions, and learn from real experiences Livagen is a Khavinson bioregulator tetrapeptide (KEDA) with significant hepatoprotective and immunomodulatory properties. Structurally similar to Epitalon, it normalizes immune and antioxidant status while restoring liver function in hepatitis conditions. Livagen is best known for its ability to decondense chromatin, activating silent genes including ribosomal genes to boost protein synthesis and cellular activity. Maximum protective effects occur during aging. Livagen works through direct effects on DNA structure and function. It decondenses chromatin (tightly packed DNA), increasing expression of certain genes and improving the 'youthful' profile of cells. The peptide activates multiple genes in lymphocytes, including previously silent ribosomal genes, boosting protein synthesis and cell activity. It exhibits hepatoprotective effects through normalizing immune and antioxidant status in liver tissue.